SBPWG:Meetings/Nov 15 2011: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 4: Line 4:


'''November 15th 6:30-8:30pm @ UCSF Mission Bay (room TBA)'''
'''November 15th 6:30-8:30pm @ UCSF Mission Bay (room TBA)'''
* [http://bioeng.berkeley.edu/cv/canderson.php '''Chris Anderson'''], assistant professor of Bioengineering at UC Berkeley and SynBERC PI, will join us to pitch, discuss and get feedback on several prospective biosafety-related projects addressing challenges in biological design, education and management.
* [http://bioeng.berkeley.edu/cv/canderson.php '''Chris Anderson'''], assistant professor of Bioengineering at UC Berkeley and SynBERC PI, joined the working group to pitch, discuss and get feedback on several prospective biosafety-related projects addressing challenges in biological design, education and management.
* '''Dinner''' provided by [http://synberc.org/ SynBERC]


===Attendees===
===Attendees===
Line 24: Line 23:


===Slides===
===Slides===
See slides [[Media:AndersonBiosafety.ppt | here]]


===Audio===
===Audio===
Download audio file [[Media:AndersonSBPWG.wav | here]]


===Pictures===
===Pictures===
[[Image:AndersonSBPWGpic.JPG]]
===Notes===
Notes transcribed by Ellick Chan
Please see the timestamps below to jump to a particular section.
16:00
*Start
*Working Group Origins at Synberc Spring retreat. Issues covered in practices. Translation, safety, security.
*Recombinant DNA, film
*Discovery Days science festival
*Biotech bootcamp
18:30
* Megan intro to Safety issues
19:00
* Chris: topics covered
**1) Containment
**2) Training
**3) Assessing risk
Don't want people making smallpox - not directly issue of synthetic bio. No one is working in that area.
Politics of biosafety - economics. Models for risk. Responding to risks. No financial collapse. Actively mitigate risk.
23:00
* Making an effective containment strategy - Auxotrophy
* Self-kill device in cell: problems
*containment of org
**codon swapping
**containment of DNA
**Dapd auxotropes
**unnatural amino acid dependence
**self destruct device
**synthetic auxotrophes
*What's the edit distance to something dangerous?
*What is dangerous?
*Lack of a theory to assess danger
28:00
*modifications cannot escape by complementation
*cannot revert through natural mutation
*sufficiently inexpensive to use in a bioreactor
*no adverse impact on viability of the cell
*be extensible to industrially relevant organisms
31:00
*pick a gene that can't be knocked out or complemented
*small molecule dependency
*allele exchange of new copy with mutant copy
*300 essential genes in ecoli
*tour based selection system
36:00
*another paper based on a similar technique
* politics
* design to contain nature. if it breaks out, it may be our fault.
* what's the bar for regulation?
* assay to prove safety/effectiveness
* not our role to set our own bar - someone else should set it
39:00
* ques: academic research on rates? chris - industry will say so
41:00
*training
*NSF needs curriculum for SynBERC
*Berkeley has classes, but most other institutions don't
*Ethics class?
*Online training module for biosafety
*heart of the problem - no theory on safety
*BUA - Biological Use Authorization -> NIH guidelines
*explosion of genes - no one knows all the risks of them off the top of their head
49:00
*risk assessment
*6 categories
**virulence
**environmental stability
**communicability
**quantity
**vaccine
**allergenicity
**potential for nefarious use
* sign off by committee if necessary
* never seen them say no. may give you recommendations
* rarely/never re-review in the case of new identified risk
54:00
*quizzes are basically a checklist of thoughts that the student should consider
* megan - does such a flowchart exist?
* biosafety guys aren't that scared of synth bio compared to other risks
* subjective questions
* risk should be considered from factors other than the originating organism
64:00
* assessment
* risk based on features
* if it can be programmed, there should be enough formalization to do so
* formalism simplifies things
* evaluation of risk depends on biologist's perspective
* first attempt
70:00
* minimize risk - example in radiation safety
* payload delivery
* risk group is max risk at any stage
* transposon not caught
* chassis can be dangerous
* device can be more dangerous than sum of its components
* substance could be dangerous in a different context
80:00
* unintentional promoter can express gene in unknown ways
* accidental recombination
* act ontology
** feature, family, device
*autorepression device
88:00
* verification and synthesis
* families - by hand
* features - partially automated
* main issue: how to populate list
* all knowledge in literature, but not enough manpower to pursue
* inference of devices resulting from modifications
92:00
*map dangerous functionality to devices
* scenarios of things that are dangerous, but not obviously dangerous
* engineered peanut allergy on salmonella
* curate high level families for danger
* what's the difference between a strain (cell+genome+plasmid mods) and a device(modification, composition of devices can create a strain)?
* strains as combination of devices. complex network.
* look at interactions between added features + original genome
100:00
* Peanut peptide combining with transporter
* Megan: is there a theory on what constitutes danger on a given agent. Weaponization of anthrax - what's the special knowledge needed to make it harmful
* 2001 list doesn't consider starting path and possible paths to dangerous agents
* megan: can we classify existing dangerous agents and process of creation?
* megan: how do we hedge our bets in making sure we're doing good work in this area? From DARPA's perspective? Safe chassis development vs automated monitoring vs surveillance vs forensics
* megan: partnerships/funding
* nsf cares about training
* containment
* megan: orthogonal genome vs selective growth environment
112:00
* orthogonal genomes very academic, but probably not industrializable - whole platform required to make this work
* what are axes of risk?
* danger from synergistic reaction adding to risk
* expert system, review committee
120:00
* megan: is there a politically-safe way to get a group to look at these issues? what would pr think?
* most of these are obvious
* is there an arms race for risk assessment schemes?
* ACT theory is open knowledge
* value will be in list of devices to query for risk
* this can be used to find dangerous devices…
Wrap-up:
* Naming devices and rubric is interesting
* Doing exercise around context of training module
* Siebel foundation event coming up
* New ways to fund biosafety
* OSTP request for info - december 6th
* Leaders in practice, 1 week bootcamp in summer - in DC

Latest revision as of 23:51, 17 November 2011

Home        About        Members        Meetings        Gaps        Discussion        Resources       



Meeting Notes: November 15 2011

November 15th 6:30-8:30pm @ UCSF Mission Bay (room TBA)

  • Chris Anderson, assistant professor of Bioengineering at UC Berkeley and SynBERC PI, joined the working group to pitch, discuss and get feedback on several prospective biosafety-related projects addressing challenges in biological design, education and management.

Attendees

  • Megan Palmer (Stanford)
  • Ryan Ritterson (UCSF)
  • Jay Vowles (Stanford)
  • Connie Eaves (UCSF)
  • Veronica Zepeda (UCSF)
  • Andy Chang (Stanford)
  • Josh Wolf (UCSF)
  • Nathan Hillson (JBEI)
  • Kevin Costa (SynBERC)
  • Chris Anderson (Berkeley)
  • Derek Greenfield (LS9)
  • Mike Fero (Teselagen)
  • Eduardo Abeliuk (Teselagen)
  • Ellick Chan (Stanford)

Slides

See slides here

Audio

Download audio file here

Pictures

Notes

Notes transcribed by Ellick Chan

Please see the timestamps below to jump to a particular section.

16:00

  • Start
  • Working Group Origins at Synberc Spring retreat. Issues covered in practices. Translation, safety, security.
  • Recombinant DNA, film
  • Discovery Days science festival
  • Biotech bootcamp


18:30

  • Megan intro to Safety issues


19:00

  • Chris: topics covered
    • 1) Containment
    • 2) Training
    • 3) Assessing risk

Don't want people making smallpox - not directly issue of synthetic bio. No one is working in that area.

Politics of biosafety - economics. Models for risk. Responding to risks. No financial collapse. Actively mitigate risk.


23:00

  • Making an effective containment strategy - Auxotrophy
  • Self-kill device in cell: problems
  • containment of org
    • codon swapping
    • containment of DNA
    • Dapd auxotropes
    • unnatural amino acid dependence
    • self destruct device
    • synthetic auxotrophes
  • What's the edit distance to something dangerous?
  • What is dangerous?
  • Lack of a theory to assess danger


28:00

  • modifications cannot escape by complementation
  • cannot revert through natural mutation
  • sufficiently inexpensive to use in a bioreactor
  • no adverse impact on viability of the cell
  • be extensible to industrially relevant organisms


31:00

  • pick a gene that can't be knocked out or complemented
  • small molecule dependency
  • allele exchange of new copy with mutant copy
  • 300 essential genes in ecoli
  • tour based selection system


36:00

  • another paper based on a similar technique
  • politics
  • design to contain nature. if it breaks out, it may be our fault.
  • what's the bar for regulation?
  • assay to prove safety/effectiveness
  • not our role to set our own bar - someone else should set it


39:00

  • ques: academic research on rates? chris - industry will say so


41:00

  • training
  • NSF needs curriculum for SynBERC
  • Berkeley has classes, but most other institutions don't
  • Ethics class?
  • Online training module for biosafety
  • heart of the problem - no theory on safety
  • BUA - Biological Use Authorization -> NIH guidelines
  • explosion of genes - no one knows all the risks of them off the top of their head

49:00

  • risk assessment
  • 6 categories
    • virulence
    • environmental stability
    • communicability
    • quantity
    • vaccine
    • allergenicity
    • potential for nefarious use
  • sign off by committee if necessary
  • never seen them say no. may give you recommendations
  • rarely/never re-review in the case of new identified risk


54:00

  • quizzes are basically a checklist of thoughts that the student should consider
  • megan - does such a flowchart exist?
  • biosafety guys aren't that scared of synth bio compared to other risks
  • subjective questions
  • risk should be considered from factors other than the originating organism


64:00

  • assessment
  • risk based on features
  • if it can be programmed, there should be enough formalization to do so
  • formalism simplifies things
  • evaluation of risk depends on biologist's perspective
  • first attempt

70:00

  • minimize risk - example in radiation safety
  • payload delivery
  • risk group is max risk at any stage
  • transposon not caught
  • chassis can be dangerous
  • device can be more dangerous than sum of its components
  • substance could be dangerous in a different context


80:00

  • unintentional promoter can express gene in unknown ways
  • accidental recombination
  • act ontology
    • feature, family, device
  • autorepression device

88:00

  • verification and synthesis
  • families - by hand
  • features - partially automated
  • main issue: how to populate list
  • all knowledge in literature, but not enough manpower to pursue
  • inference of devices resulting from modifications


92:00

  • map dangerous functionality to devices
  • scenarios of things that are dangerous, but not obviously dangerous
  • engineered peanut allergy on salmonella
  • curate high level families for danger
  • what's the difference between a strain (cell+genome+plasmid mods) and a device(modification, composition of devices can create a strain)?
  • strains as combination of devices. complex network.
  • look at interactions between added features + original genome


100:00

  • Peanut peptide combining with transporter
  • Megan: is there a theory on what constitutes danger on a given agent. Weaponization of anthrax - what's the special knowledge needed to make it harmful
  • 2001 list doesn't consider starting path and possible paths to dangerous agents
  • megan: can we classify existing dangerous agents and process of creation?
  • megan: how do we hedge our bets in making sure we're doing good work in this area? From DARPA's perspective? Safe chassis development vs automated monitoring vs surveillance vs forensics
  • megan: partnerships/funding
  • nsf cares about training
  • containment
  • megan: orthogonal genome vs selective growth environment


112:00

  • orthogonal genomes very academic, but probably not industrializable - whole platform required to make this work
  • what are axes of risk?
  • danger from synergistic reaction adding to risk
  • expert system, review committee


120:00

  • megan: is there a politically-safe way to get a group to look at these issues? what would pr think?
  • most of these are obvious
  • is there an arms race for risk assessment schemes?
  • ACT theory is open knowledge
  • value will be in list of devices to query for risk
  • this can be used to find dangerous devices…


Wrap-up:

  • Naming devices and rubric is interesting
  • Doing exercise around context of training module
  • Siebel foundation event coming up


  • New ways to fund biosafety
  • OSTP request for info - december 6th
  • Leaders in practice, 1 week bootcamp in summer - in DC